相关实验视频
Updated: Jun 28, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
87
在患有类风湿性关节炎的患者中,CCR9+CD4+T细胞与疾病活性有关
Geng Lina1,2, Qiang Cuixin1, Zhang Xia3
1Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Medicine
|April 19, 2024
概括
在类风湿性关节炎 (RA) 患者中,化基因受体9 (CCR9) + CD4 + T 细胞的升高与疾病活性有关. 这些细胞在血液和突液中发现,与关键的RA生物标志物相关联.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 突中CD4+T细胞的透对于类风湿性关节炎 (RA) 的发病过程至关重要.
- 了解导致CD4+T细胞水平升高和RA疾病活动的因素至关重要.
研究的目的:
- 调查RA中CD4+T细胞水平增加的原因.
- 探索CD4+T细胞子集与RA疾病活性之间的关系.
主要方法:
- 流细胞计用于分析CR9+CD4+T细胞和CD4+T细胞上的CR9表达.
- 通过ELISA和化学发光免疫测试测量了INTERLEUKIN (IL) -17A和IL-6水平.
- 该研究包括55名RA患者 (28名RA活跃,27名RA不活跃) 和22名健康对照.
主要成果:
- 在活跃的RA患者的外周血液 (PB) 和突液 (SF) 中,CCR9+CD4+T细胞和CCR9的表达显着更高.
- 与RA患者的PB相比,SF的CR9+CD4+T细胞,IL-6和IL-17A水平较高.
- 在CD4+ T细胞上的CCR9表达与RA疾病活性标志物 (ESR,hs-CRP,RF,anti-CCP) 有正相关.
结论:
- 在RA患者的PB和SF中,CCR9+CD4+T细胞都升高.
- 这些细胞与增加的疾病活性和RA的炎症标志物有关.
- CCR9+CD4+T细胞代表了RA疾病活动的潜在生物标志物.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
T Cell Activation and Clonal Selection
716
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
716
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Cytotoxic T Cells-mediated Immune Response
904
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
904
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
136
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
136

